Lasa Supergenerics Share Price

NSE
LASA •
BUY
The current prices are delayed, login or Open Demat Account for live prices.
Lasa Supergenerics Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Lasa Supergenerics Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
44.85% Fall from 52W High
-22
Dividend yield 1yr %
0

Lasa Supergenerics shareholding Pattern

Promoter
53.6%
Public
46.4%
Promoter
53.6%
Public
46.4%
Promoter
53.6%
Public
46.3%
Promoter
53.6%
Public
46.3%
Promoter
53.6%
Foreign Institutions
0.1%
Public
46.2%
Promoter
53.6%
Public
46.3%

Lasa Supergenerics Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
9
Bearish Moving Averages
7
5Day EMA
18.10
10Day EMA
17.80
12Day EMA
17.80
20Day EMA
17.80
26Day EMA
18.00
50Day EMA
19.10
100Day EMA
21.20
200Day EMA
23.20
5Day SMA
18.20
10Day SMA
17.60
20Day SMA
17.60
30Day SMA
17.70
50Day SMA
19.00
100Day SMA
22.40
150Day SMA
23.80
200Day SMA
24.70
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
67752 Rs
91800 Rs
Week Rs
75899 Rs
106275 Rs
Month Rs
93727 Rs
168049 Rs
Resistance & Support
18.42
Pivot
Resistance
First Resistance
18.85
Second Resistance
19.22
Third Resistance
19.65
Support
First Support
18.05
Second support
17.62
Third Support
17.25
Relative Strength Index
54.46
Money Flow Index
77.71
MACD
-0.21
MACD Signal
-0.47
Average True Range
1.03
Average Directional Index
24.59
Rate of Change (21)
4.94
Rate of Change (125)
-32.52

Lasa Supergenerics Latest News

16 MAY 2025 | Friday

Lasa Supergenerics Ltd - 540702 - Board Meeting Intimation for The Quarter And The Year Ended March 31, 2025

13 MAY 2025 | Tuesday

Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Resignation of Director

06 MAY 2025 | Tuesday

Lasa Supergenerics Ltd - 540702 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Disclosure With The Reference To Notice Of EGM Held On Saturday, February 22, 2025

View More

Lasa Supergenerics Company background

Founded in: 2016
Managing director: Omkar P Herlekar
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chainfrom discoverytodelivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad Chiplun, in the Konkan region of Maharashtra. It specialises in catalyst chemistry and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain, the Company is fully backward integrated for its key moleculesfrom discovery research up to fullscale bulk production. The Companys marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future.The Company announced the launching of 2 new block buster products with alltime strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit with a total capacity of 20 MT. It has got huge demand all over the globe as it is manufactured and have strong entry barriers. Likewise, this product fits in product selection criteria, through which the Company is confident of grabbing significant market share.The Scheme of Amalgamation of Harishree Aromatics and Chemicals Private Limited with the Company and their respective shareholders was approved by Honble National Company Law Tribunal on December 23, 2022 which became effective from January 04, 2023 in year 202223. Following the said Scheme of Amalgamation, 1000 Equity Shares of Rs 10/ per share of the Company was allotted for every 35 Equity Shares of Rs 10/ of Harishree Aromatics and Chemicals Private Limited on January 5, 2023. The company received WHO Certificate of Good Manufacturing Practices from the Food and Drug Administration authorities for its manufacturing facility situated at Khed, Ratnagiri. The Company has alliances with leading Indian and global animal health care conglomerates and uses Good Manufacturing Practice (GMP) and worldclass technologies in its operations. The Company is managed by a consortium of technocrats, including its Chairman and Managing Director Mr. Omkar P. Herlekar who are impelled by passion and propelled by niche innovation. The leadership team, which is guided by these values, is well positioned to lead into the future.
Read More

Lasa Supergenerics FAQs

Lasa Supergenerics share price is ₹18.55 in NSE and ₹18.58 in BSE as on 16/5/2025.

Lasa Supergenerics share price in the past 1-year return was -21.73. The Lasa Supergenerics share hit a 1-year low of Rs. 16.56 and a 1-year high of Rs. 33.49.

The market cap of Lasa Supergenerics is Rs. 92.54 Cr. as of 16/5/2025.

The PE ratios of Lasa Supergenerics is 0 as of 16/5/2025.

The PB ratios of Lasa Supergenerics is 1.01 as of 16/5/2025

You can easily buy Lasa Supergenerics shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Lasa Supergenerics stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -